Stay updated on Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Added a Locations section with the Washington site listed. The footer revision note was updated to v3.3.3 and the HHS Vulnerability Disclosure and Washington Locations entries were removed.
    Difference
    0.2%
    Check dated 2025-12-22T22:28:45.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    No Change Detected
  5. Check
    31 days ago
    Change Detected
    Summary
    Revision updated from v3.3.1 to v3.3.2 on the page; no study content or user-facing details appear to have changed.
    Difference
    0.1%
    Check dated 2025-12-01T16:21:02.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Minor version update from v3.2.0 to v3.3.1. No changes to the study content or trial details are observed.
    Difference
    0.1%
    Check dated 2025-11-24T10:59:49.000Z thumbnail image
  7. Check
    46 days ago
    Change Detected
    Summary
    The government operating status banner at the top was removed. The study details, eligibility criteria, locations, and outcomes on the page remain unchanged.
    Difference
    0.4%
    Check dated 2025-11-17T06:10:12.000Z thumbnail image
  8. Check
    60 days ago
    Change Detected
    Summary
    No significant changes to core trial information were detected; only minor formatting adjustments were observed, To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-11-03T00:45:52.000Z thumbnail image
  9. Check
    89 days ago
    Change Detected
    Summary
    Updated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.
    Difference
    3%
    Check dated 2025-10-05T08:14:50.000Z thumbnail image

Stay in the know with updates to Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Umbralisib Plus Pembrolizumab in Hodgkin Lymphoma Clinical Trial page.